Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.80
+0.44008.21%
Post-market: 5.820.0199+0.34%19:59 EDT
Volume:2.61M
Turnover:14.81M
Market Cap:446.68M
PE:-4.33
High:5.90
Open:5.50
Low:5.25
Close:5.36
Loading ...

Executive reshuffles: TWO, CYBR, PFG and ALT

seekingalpha
·
17 Nov 2024

Stock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients

Stock Track
·
16 Nov 2024

Altimmune presents data on effect of pemvidutide on inflammatory lipids

TIPRANKS
·
16 Nov 2024

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire
·
16 Nov 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Nov 2024

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
14 Nov 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley

TIPRANKS
·
14 Nov 2024

Altimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. Wainwright

TIPRANKS
·
14 Nov 2024

Altimmune (ALT) Receives a Buy from Evercore ISI

TIPRANKS
·
13 Nov 2024

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Business Wire
·
13 Nov 2024

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024

Zacks Small Cap Research
·
13 Nov 2024

Altimmune stock rallies 30% on business updates, UBS buy rating

seekingalpha
·
13 Nov 2024

Altimmune Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Altimmune Initiated at Buy by UBS

Dow Jones
·
12 Nov 2024

UBS Initiates Altimmune at Buy With $26 Price Target

MT Newswires Live
·
12 Nov 2024

Altimmune Q3 2024 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $5.000K Beat $833.330 Estimate

Benzinga
·
12 Nov 2024

Altimmune initiated with a Buy at UBS

TIPRANKS
·
12 Nov 2024

Altimmune Names Greg Weaver Chief Financial Officer

MT Newswires Live
·
11 Nov 2024

Altimmune names Greg Weaver as CFO

seekingalpha
·
11 Nov 2024